Trial of the "Mittin" Intervention to Improve Contraceptive Side Effect Counseling and Follow-up in Ethiopia
- Sponsor
- University of California, San Francisco
- Study ID
- NCT07301281
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Contraception
- Side Effects
Eligibility Criteria
- Sex
- FEMALE
- Age
- 15 Years - 49 Years
- Healthy Volunteers
- Not accepted
Interventions
- Mittin — BEHAVIORALMittin intervention consists of the following components: 1. Educational posters and handouts to raise awareness of the right to contraceptive choice and to switch methods if side effects become intolerable 2. Decision support tools for providers to aid women in weighing the risks and benefits of potential side effects during in-person counseling 3. On-demand and proactive virtual side effects counseling and referrals via a call center.
Study Details
The goal of this clinical trial is to learn if the "Mittin" intervention can improve women's ability to manage their fertility in line with their preferences among women aged 15-49 using hormonal contraceptives or intrauterine devices and attending public health centers in Addis Ababa, Ethiopia. The main question it aims to answer is: Does the Mittin intervention increase preference-aligned fertility management, contraceptive method satisfaction, and preferred contraceptive method use among participants compared to standard care? Researchers will compare women's outcomes in health centers providing the Mittin intervention to women's outcomes in health centers that offer standard care to see if Mittin improves women's ability to act in line with their contraceptive preferences. Participants will * Receive either standard contraception services (control arm) or enhanced services (intervention arm) * Participate in a survey at the beginning of the study * Participate in surveys 4 and 8 months later
Key Dates
- First listed
- Dec 24, 2025
- Start date
- Feb 28, 2026
- Status verified
- Dec 2025
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 2,715 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- No Intervention: Standard of care armHealth centers randomized to the standard of care arm will continue offering standard of care contraceptive counseling as per Ethiopian Ministry of Health guidelines. After completion of the c-RCT, the control arm health centers will receive Mittin materials for use on-site (counseling tools, waiting room posters, and educational handouts).
- Experimental: Mittin Intervention armHealth centers randomized to receive the Mittin intervention will receive staff training and materials (counseling tools, waiting room posters, and educational handouts) necessary to offer Mittin's side effects counseling and support model in their facilities. Women enrolled in the study in intervention health centers will receive proactive follow-up calls from call center agents to offer support after initiating a new contraceptive method. The call center will also be available on-demand to any person who desires support related to contraceptive options or side effects.
Primary Outcome Measure
Preference-Aligned Fertility Management (PFM) Index [ Time Frame: Measured at 4 and 8 months ]
Central Contacts
- Kelsey Holt, ScD617-455-2693
Related Studies
- Evaluation of the Efficacy, Safety, and Tolerability of LevoCeptPHASE3 · Not Yet Recruiting · Sebela Women's Health Inc. · Berkeley, California
- Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum PeriodRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Etonogestrel Implant as Emergency ContraceptionPHASE4 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day StartPHASE4 · Recruiting · University of Utah · San Jose, California